Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.

Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N.

Bioorg Med Chem. 2010 Oct 1;18(19):6977-86. doi: 10.1016/j.bmc.2010.08.026. Epub 2010 Aug 14.

PMID:
20817538
2.

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G.

Blood. 2007 Dec 1;110(12):4055-63. Epub 2007 Aug 24.

3.

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.

Levinson NM, Boxer SG.

PLoS One. 2012;7(4):e29828. doi: 10.1371/journal.pone.0029828. Epub 2012 Apr 6.

4.

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.

Deadman BJ, Hopkin MD, Baxendale IR, Ley SV.

Org Biomol Chem. 2013 Mar 21;11(11):1766-800. doi: 10.1039/c2ob27003j. Epub 2012 Dec 18. Review.

PMID:
23247657
5.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
6.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P.

Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.

7.

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

Jabbour E, Kantarjian H, Cortes J.

Semin Hematol. 2010 Oct;47(4):344-53. doi: 10.1053/j.seminhematol.2010.06.002. Review.

PMID:
20875551
8.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

9.

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H.

IDrugs. 2007 Jul;10(7):468-79.

PMID:
17642017
10.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

11.

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M.

Int J Cancer. 2010 Nov 1;127(9):2119-28. doi: 10.1002/ijc.25233.

12.

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.

Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV.

Leukemia. 2004 Aug;18(8):1352-6.

PMID:
15201856
13.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
14.

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.

Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M.

Biochem Pharmacol. 2010 Mar 1;79(5):688-97. doi: 10.1016/j.bcp.2009.10.009. Epub 2009 Oct 27.

PMID:
19874801
15.

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.

von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J.

Blood. 2005 Feb 15;105(4):1652-9. Epub 2004 Sep 30.

16.
17.

Exploiting the promiscuity of imatinib.

Lee SJ, Wang JY.

J Biol. 2009;8(3):30. doi: 10.1186/jbiol134. Epub 2009 Apr 15. Erratum in: J Biol. 2010;8:82.

18.

Nilotinib for the treatment of chronic myeloid leukemia.

Kim TD, Dörken B, le Coutre P.

Expert Rev Hematol. 2008 Oct;1(1):29-39. doi: 10.1586/17474086.1.1.29.

PMID:
21083005
19.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):420.

PMID:
24629639
20.

Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.

Yamakawa Y, Hamada A, Uchida T, Sato D, Yuki M, Hayashi M, Kawaguchi T, Saito H.

Biol Pharm Bull. 2014;37(8):1330-5.

Supplemental Content

Support Center